A long time ago, when CTIX was just a startup with 2 preclinical drugs and almost no following, management told me they thought buyout bids would start at around $15 billion if early and mid stage clinical trials proved out. They have. I don’t think that assessment has changed, though as management of a now late stage development biopharma, they are much more careful about what they say and how they say it.